These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 9892267)

  • 21. Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients.
    Csiky B; Sulyok E; Lakatos O; Wittmann I; Martens-Lobenhoffer J; Bode-Boger SM
    Nephron Clin Pract; 2008; 108(2):c127-34. PubMed ID: 18230915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin.
    Raj DS; Vincent B; Simpson K; Sato E; Jones KL; Welbourne TC; Levi M; Shah V; Blandon P; Zager P; Robbins RA
    Kidney Int; 2002 Feb; 61(2):697-704. PubMed ID: 11849413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Symmetric dimethylarginine is an independent predictor of intradialytic hypotension.
    Mangoni AA; Hewitson CL; Woodman RJ; Whiting MJ; McAteer-Carr B; Barbara JA
    Am J Hypertens; 2008 Aug; 21(8):955-9. PubMed ID: 18551101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
    Toutouzas K; Riga M; Stefanadi E; Stefanadis C
    Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients.
    Zoccali C; Enia G; Tripepi G; Panuccio V; Mallamaci F
    Perit Dial Int; 2005 Feb; 25 Suppl 3():S84-7. PubMed ID: 16048265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of nitric oxide synthase inhibitors and their use to reverse hypotension associated with cancer immunotherapy.
    Griffith OW; Kilbourn RG
    Adv Enzyme Regul; 1997; 37():171-94. PubMed ID: 9381971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.
    Jacobi J; Tsao PS
    Am J Nephrol; 2008; 28(2):224-37. PubMed ID: 17960061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology of dialysis hypotension: an update.
    Daugirdas JT
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 4):S11-7. PubMed ID: 11602456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitric oxide production with PMMA membrane.
    Amore A; Coppo R
    Contrib Nephrol; 1999; 125():182-96. PubMed ID: 9895440
    [No Abstract]   [Full Text] [Related]  

  • 31. The venous system and dialysis-associated hypotension.
    Kooman JP; van Hooff JP; Leunissen KM
    Contrib Nephrol; 1994; 106():99-105. PubMed ID: 8174386
    [No Abstract]   [Full Text] [Related]  

  • 32. Atherogenesis and the arginine hypothesis.
    Cooke JP; Oka RK
    Curr Atheroscler Rep; 2001 May; 3(3):252-9. PubMed ID: 11286647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period.
    Kang ES; Tevlin MT; Wang YB; Chiang TM; Cardenas R; Myers LK; Acchiardo SR
    Am J Med Sci; 1999 Jan; 317(1):9-21. PubMed ID: 9892267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
    Kielstein JT; Bode-Böger SM; Frölich JC; Haller H; Böger RH
    Kidney Int Suppl; 2001 Feb; 78():S9-13. PubMed ID: 11168975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications for the role of endogenous nitric oxide inhibitors in hemodialysis hypotension.
    Kang ES; Acchiardo SR; Kang AH
    Free Radic Res; 2001 Oct; 35(4):341-65. PubMed ID: 11697132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.
    Fleck C; Schweitzer F; Karge E; Busch M; Stein G
    Clin Chim Acta; 2003 Oct; 336(1-2):1-12. PubMed ID: 14500028
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.